During the 2009-2010 immunization campaign against pandemic H1N1, some people reported having allergic-like reactions (anaphylaxis(a shock-like reaction), hives, swelling, etc.). A vaccine allergy may be more or less severe or intense. Patients may have skin reactions (rash with or without itching), respiratory problems (cough, spasm of the airways), angioedema (swelling) of various body parts (face, eyelids, throat etc.) and circulatory problems (low blood pressure or shock). Anaphylaxis is a severe allergic reaction that can sometimes be fatal. Other people vaccinated against pandemic H1N1 had an oculo-respiratory syndrome. Oculo-respiratory syndrome (ORS) is also a reaction to the influenza vaccine, which includes symptoms such as bilateral conjunctivitis (red eyes) with swelling of the face or respiratory symptoms (chest tightness, coughing, a sensation of throat closure, difficulty swallowing, hoarseness, wheezing or difficulty breathing). The investigators know that ORS is not a true allergic reaction. Because many signs and symptoms of ORS are similar to those observed during an allergic reaction, it is often difficult to distinguish ORS from an allergic reaction. This study will compare three groups of patients: those who had allergic-like reactions, those who had ORS and vaccinated individuals who had no such adverse events. Pregnant women cannot participate in this study. The study has three goals. First, the investigators want to determine, among those who had allergic-like reactions after influenza vaccination, what proportion (percentage) of these people are actually allergic to the vaccine or its components. Second, among those who are not allergic to the vaccine, which other processes may have caused these symptoms. Finally, the investigators will try to identify whether there are features that distinguish patients who have a true allergic reaction from those affected by ORS, and those that had no adverse events.
Study Type
OBSERVATIONAL
Enrollment
138
Centre Hospitalier Charles Lemoyne
Greenfield Park, Quebec, Canada
Centre Hospitalier Universitaire de Montréal
Montreal, Quebec, Canada
Montreal General Hospital
Montreal, Quebec, Canada
Montreal Children's Hospital
Montreal, Quebec, Canada
Hôpitale Ste-Justine
Montreal, Quebec, Canada
Centre Hospitalier Universitaire de Québec
Québec, Quebec, Canada
Centre Hospitalier et Universitaire de Sherbrooke
Sherbrooke, Quebec, Canada
proportion of individuals with IgE mediated allergic reaction
The overall objective of this clinical investigation is to estimate the proportion of individuals with IgE mediated allergic reaction to Arepanrix or its components among patients with anaphylaxis/allergic reaction after pH1N1 vaccination, and the proportion that are allergic to the 2010-2011 trivalent inactivated seasonal influenza vaccine (TIV).
Time frame: one year
Biomarkers that may allow differentiation between ORS and type I hypersensitivity
We will try to identify biomarkers that may allow differentiation of patients with ORS and those with type I hypersensitivity to the vaccine.
Time frame: two year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.